Form SC 13D/A Valeant Pharmaceuticals Filed by: Pershing Square Capital Management, L.P.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Buy Valeant Pharmaceuticals (VRX) Ahead of Investor Day Catalyst - Guggenheim
November 24, 2015 8:02 AM ESTGuggenheim analyst Louise Chen reiterated a Buy rating and $195 on Valeant Pharmaceuticals (NYSE: VRX) saying the stock has bottomed and multiple expansion will drive shares higher. Chen recommends buying ahead of the December 16, 2015 investor day catalyst.
"Concerns regarding high-priced drugs and specialty pharmacies have weighed on VRX shares since mid-September,... More
Pershing Square Capital Affirms Lifting Valeant Pharma (VRX) Stake to 9.9%
November 23, 2015 5:28 PM ESTPershing Square Capital Management, L.P., the investment manager for Pershing Square Holdings, Ltd. has updated its Schedule 13D with the United States Securities and Exchange Commission, disclosing that various funds it manages increased their beneficial ownership of Valeant Pharmaceuticals International, Inc. (NYSE: VRX), to 9.9% of shares outstanding.
... MoreAckman's Pershing Square Capital Raises Stake in Valeant Pharmaceuticals (VRX) to 9.9%
November 23, 2015 5:17 PM ESTIn an amended 13D filing on Valeant Pharmaceuticals (NYSE: VRX), Bill Ackman's hedge fund Pershing Square Capital disclosed a 9.9%, or 34,118,551 share, stake in the company. This is up 75.20% from the 19,473,933 shares held at the end of the latest quarter ending September 30, 2015.
For more notable holders of Valeant Pharmaceuticals stock click here. For more information on Pershing Square Capital click... More
Pershing Square Capital Raises Stake in Valeant Pharma (VRX) to 9.9%
November 23, 2015 5:16 PM ESTIn a 13D filing on Valeant Pharma (NYSE: VRX), hedge fund Pershing Square Capital disclosed a 9.9%, or 34,118,551 share, stake in the company. This is up 75.20% from the 19,473,933 shares held at the end of the latest quarter ending September 30, 2015.
For more notable... More
